Genmab — Marts 2016
-
Sectorrotation fortsætter IBB - 1,8% ned. Derfor fortsætter det anonyme udsalg i Genmab
-
Kan det tænkes, der er kommet et bud, Gen mener er alt for lavt fra et andet firma og derfor prikker til JNJ for ligesom at sige, de skal komme ud af busken med et stort bud, hvis de vil have butikken. Måske fordi den anden part kunne tænke sig at hæve buddet og fordi Jan hellere vil sælge til JNJ end andre?
-
The application is based on the results from a Phase III study, COMPLEMENT 2, which evaluated ofatumumab in combination with FC versus FC alone in patients with relapsed CLL. Top-line results from this trial were reported in April 2015. The study met the primary endpoint with a median progression free survival in patients receiving ofatumumab in combination with FC of 28.9 months compared to 18.8 months in patients receiving FC alone (HR =0.67, p=0.0032).
-
"Today's regulatory submission in Europe brings us another step closer to making ofatumumab available to a wider group of patients with relapsed CLL and we look forward to the EMA's response," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab
-
Det var svært at nå før slutauktionen.
-
Børsen fik den hurtigt på: http://penge.borsen.dk/artikel/1/321262/genmab_vil_have_udvidet_arzerra-godkendelse_i_europa.html
-
Hermed ordret oversættelse (i hvertfald så tæt på som jeg lige kan komme):
-
Van Winkel ignites the fire by referring to the fact that January was the worst month ever for biotech. “This is a good moment to get onboard”. He subsequently continues to appraise his company Genmab that has a fabulous drug with its cancer medicine Darzalex.
The market has acknowledged Genmab as ripe for takeover for two years now. Van der Winkel is not declining (or taking away / putting away / opposing) the rumors. He, to the contrary, refers to the takeover of Pharmacyclics by Abbvie for 2 -
21B USD. Johnson and Johnson were outsmarted by this a year ago. Van de Winkel: “J&J won’t let this happen once more. They, on top of this, have 35B “stored” overseas. A takeover is becoming more and more appealing to them”.
“Not that I want to let go of Genmab” he continues. But if it comes that far, then it will be a friendly takeover. However, I expect a premium of 100% on the current share price.” -
Og det var så af de mest følsomme oplysninger i Hollandsk artikel...
-
Jeg ved ikke, om det er en DuoBody.??..https://clinicaltrials.gov/ct2/show/NCT02454270?term=JNJ-64052781&rank=1
) Protein in Subjects With Relapsed or Refractory B-cell MalignanciesHello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind